The pharmaceutical industry is invigorated by the promise of quicker regulatory decisions, more targeted treatments and a pickup in new drug approvals as the effect of a major wave of patent expiries subsides. "It's a very exciting time in terms of advances in science and technology," FDA Commissioner Dr. Margaret Hamburg said. Signs of renewed investor confidence can be seen in stock prices.

Full Story:

Related Summaries